kondapa Naidu Bobba

Assistant professor

University of Tennessee
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (64)

Purpose: CD46 is highly expressed across multiple cancer types, including prostate cancer and multiple myeloma. We have developed CD46-targeting antibody–drug conjugate (ADC) and actinium-225 (225Ac)–based α particle therapy agents that demonstrated a tumor-selective therapeutic effect. We hypothesized that a treatment strategy targeting CD46 using simultaneous ADC and radioimmunotherapy methods would have synergistic therapeutic efficacy with acceptable toxicity. Experimental Design: Two CD46-targeted combination treatment strategies were evaluated: (i) co-administration of the ADC (YS5-MMAE) and 225Ac-labeled antibody ([225Ac]Macropa-PEG4-YS5) and (ii) a dual-payload radioconjugate ([225Ac]Macropa-PEG4-YS5-MMAE; R-ADC). The in vitro synergy was studied using cell viability, DNA damage, and apoptosis assays. In vivo studies were performed for biodistribution, toxicity, and therapeutic evaluation in subcutaneous, disseminated, and patient-derived xenograft models of prostate cancer and multiple myeloma. Results: Combination therapy induced synergistic G2–M arrest, increased γ-H2AX foci, and enhanced cell death compared with monotherapies. R-ADC and co-administration strategies resulted in improved tumor control and survival benefit. Conclusions: By integrating orthogonal microtubule inhibition and high–linear energy transfer α irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct’s compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.

Year:

2026

Purpose: Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) have shown promising results in prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [89Zr]DFO-YS5, and the radioimmunotherapy agent [225Ac]Macropa-PEG4-YS5, in disseminated prostate cancer tumors. Experimental Design: Microtumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [89Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [225Ac]Macropa-PEG4-YS5. Results: Quantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [225Ac]Macropa-PEG4-YS5 in microtumors compared with surrounding liver tissues, although in larger lesions (>1 mm diameter), the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with a uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response. Conclusions: Our findings highlight that [225Ac]Macropa-PEG4-YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy. See related commentary by Patel et al., p. 2847

Year:

2025

The enhanced permeability and retention (EPR) effect controls passive nanodrug uptake in tumors and may provide a high tumor payload with prolonged retention for cancer treatment. However, EPR-mediated tumor uptake and distribution vary by cancer phenotype. Thus, we hypothesized that a companion PET imaging surrogate may benefit EPR-mediated therapeutic drug delivery. We developed two 89Zr-radiolabeled nanocarriers based on 4-armed starPEG40kDa with or without talazoparib (TLZ), a potent PARP inhibitor, as surrogates for the PEG-TLZ4 therapeutic scaffold. For PET imaging, PEG-DFB4 and PEG-DFB1-TLZ3 were radiolabeled with 89Zr by replacing one or all four copis of TLZ on PEG-TLZ4 with deferoxamine B (DFB). The radiolabeled nanodrugs [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 were tested in vivo in prostate cancer subcutaneous (s.c.) xenografts (22Rv1, LTL-545, and LTL-610) and 22Rv1 metastatic models. Their EPR-mediated tumoral uptake and penetration was compared with CT26, a known EPR-high cell line. MicroPET/CT images, organ biodistribution, and calculated kinetic parameters showed high uptake in CT26 and LTL-545 and moderate to low uptake in LTL-610 and 22Rv1. MicroPET/CT and high-resolution autoradiographic images showed nanocarrier penetration into highly permeable CT26, but heterogeneous peripheral accumulation was observed in LTL-545, LTL-610, and 22Rv1 s.c. xenografts and metastatic tumors. CD31 staining of tumor sections showed homogenous vascular development in CT26 tumors and heterogeneity in other xenografts. Both [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 showed similar accumulation and distribution in s.c. and metastatic tumor models. Both nanocarriers can measure tumor model passive uptake heterogeneity. Although heterogeneous, prostate cancer xenografts had low EPR. These starPEG nanocarriers could be used as PET imaging surrogates to predict drug delivery and efficacy.

Year:

2025

Year:

2025

Figure S4: Gamma energy spectra of the tumor, blood, kidneys, and bone showing the intensities of the 213Bi and 221Fr peaks. As compared to the equilibrium gamma energy spectra of [225Ac]DOTA-YS5, increased intensity of the 213Bi was observed in kidney samples.

Year:

2025

Figure S11: Antitumor activity of [225Ac]DOTA-YS5 in subcutaneous DU145 tumors in nude mice. Tumor volume, survival analysis, and weight measurements after the injections of [225Ac]DOTA-YS5 in DU145 xenografts (n=6).

Year:

2025

Figure S10: Tumor volumes, overall survival, and body weights for the saline and fractionated dose (0.125 µCi x 3) injections in 22Rv1 xenografts. Results show delayed tumor growth and improved survival without the significant toxicity from fractionated dose treatment (n=10).

Year:

2025

Figure S9: Histology evaluation of the healthy tissues for long-term (117 days) toxicity analysis. Hematoxylin and Eosin (H&E) staining of spleen, liver, lungs, heart, and bone samples show no toxicity at 0.25 µCi or 0.5 µCi doses of [225Ac]DOTA-YS5. Scale bar: 20 µm

Year:

2025

Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues injected with [225Ac]DOTA-YS5 for day 1, day 2, day 4, and day 7.

Year:

2025

Figure S8: Acute toxicity study of the [225Ac]DOTA-YS5 in nude mice (n=5). A The body weights of mice injected with [225Ac]DOTA-YS5 showed no significant change in treatment groups over the 15 days study period. B&C: Liver and kidney function tests (B) and blood parameters (C) show no significant changes for saline vs. treated groups indicating the short-term safety of [225Ac]DOTA-YS5.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (22)

Michael J. Evans

University of California

UNITED STATES
View details

Nancy Y. Greenland

-

UNITED STATES
View details

Arun Wiita

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Li Zhang

Professor

UCSF

UNITED STATES
View details

Emily Chan

Stanford University

UNITED STATES
View details

Henry VanBrocklin

Professor/ Director of Radiopharmaceutical Research

University of California, San Francisco

UNITED STATES
View details

Jiang He

Professor

University of Virginia

UNITED STATES
View details

David M. Wilson

University of California

UNITED STATES
View details

Renuka Sriram

University of California

UNITED STATES
View details

Emily Egusa

University of California, San Francisco

UNITED STATES
View details

Prasanna Ramani

Professor

Amrita School of Engineering

View details

Lei Wang

Associate Professor - Professor

University of California, San Francisco

UNITED STATES
View details

Anil Parsram Bidkar

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

sinan wang

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Changhua Mu

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Bingchen Yu

Assistant Professor

University of Georgia

UNITED STATES
View details

Robert R. Flavell

University of California

UNITED STATES
View details

Y. Seo

University of California, San Francisco

UNITED STATES
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Megha Basak

University of California, San Francisco

UNITED STATES
View details

Scott C. Kogan

University of California, San Francisco

UNITED STATES
View details